Form 4: Royalty Pharma Executive Sells Shares
Insider Transaction (Form 4)
Christopher Hite, EVP & Chairman, Partnering of Royalty Pharma plc, sold 100,000 shares of common stock on September 22, 2026.
Summary
- Open-market sale: disposed of 96,073 Class A Ordinary Shares at $58.51 ($5,621,692) on September 22, 2026; holds 274,328 after (Indirect).
- Open-market sale: disposed of 3,927 Class A Ordinary Shares at $58.93 ($231,403) on September 22, 2026; holds 270,401 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,853,095 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Christopher Hite — Officer (EVP & Chairman, Partnering)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-22 | Open-market sale | Class A Ordinary Shares | 96,073 | $59 | $5.6M | 274,328 |
| 2026-09-22 | Open-market sale | Class A Ordinary Shares | 3,927 | $59 | $231.4K | 270,401 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-22 | Open-market sale (96,073 shares) |
| 2026-09-22 | Open-market sale (3,927 shares) |
Keywords
insider transaction, Form 4, RPRX, Royalty Pharma plc, bearish, Christopher Hite
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.